Skip to content

Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With MINOCA

Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With Myocardial Infarction With Nonobstructive Coronary Arteries

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06066177
Enrollment
100
Registered
2023-10-04
Start date
2024-01-20
Completion date
2028-10-01
Last updated
2024-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Cardiovascular Events

Keywords

Triglyceride glucose index Myocardial infarction MINOCA

Brief summary

This work was designed to explore the role of the triglyceride-glucose (TyG) index in the prediction of cardiovascular outcomes in Patients Presented with myocardial infarction with nonobstructive coronary arteries.

Detailed description

Acute myocardial infarction (AMI) remains the leading causes of high morbidity and mortality worldwide . Recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) has been increasingly recognized because of the widespread use of coronary angiography. MINOCA occurs in 5%-10% of all AMI and they are younger and more often women compared to patients with AMI and obstructive coronary artery disease (CAD). The underlying causes of MINOCA are manifold and may include plaque rupture or erosion, thromboembolism, coronary spasm, spontaneous dissection, microvascular dysfunction and supply/demand mismatch. Some non-ischemic diseases such as myocarditis may also mimic the presentation of MINOCA . Of note, several studies have found that the prognosis of MINOCA is not trivial and patients are still at considerable risks for long-term adverse cardiovascular (CV) events despite the optimal secondary prevention treatments . Thus, it is of necessity and profound implications to find potential residual risk factors and improve prognosis in MINOCA population. Insulin resistance (IR), a critical mechanism of the pathogenesis of diabetes, not only contributes to the development of cardiovascular diseases (CVD), but also significantly correlates with adverse CV outcomes. Additionally, IR often coexists with obesity, hypertension, and dyslipidemia , and all of these are well-known risk factors of CVD. Recently, the triglyceride-glucose (TyG) index derived from fasting triglyceride (TG) and fasting blood glucose (FBG) levels has been proposed as a new and valid surrogate indicator of IR . Till now, many studies have found that the TyG index is positively correlated with metabolic disorders, arterial stiffness , carotid atherogenesis , coronary artery calcification , and subclinical or symptomatic CAD. Moreover, growing evidence has showed that the TyG index is an independent predictor of poor CV outcomes in general population and in different cohorts with CAD, including patients with AMI or acute coronary syndrome (ACS) with or without diabetes

Interventions

DIAGNOSTIC_TESTTriglyceride glucose index TyG

Triglyceride glucose index is an indicator of insulin resistance

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 80 Years

Inclusion criteria

* All patients; diagnosed with myocardial infarction with nonobstructive coronary arteries (MINOCA) * clinical symptoms * ECG : ischemic changes with or without ST segment elevation * Echocardiograpy : segmental wall motion abnormalities (SWMA) * positive cardiac enzymes * Coronary angiography: insignificant lesions ,the absence of culprit obstructive coronary artery disease (epicardial coronary artery stenosis ≥50%)

Exclusion criteria

* All non confirmed diagnosis of MINOCA * cardiac * non-ischemic cardiomyopathies * non-cardiac * pulmonary embolism * stroke * sepsis * ARDS

Design outcomes

Primary

MeasureTime frameDescription
Incidence of major adverse cardiovascular events (MACE)along one year follow up .including * all-cause death, * reinfarction, * stroke, * re-intervention * hospitalization for unstable angina or heart failure)

Contacts

Primary ContactAhmed Gamal Thabit Mohamed
ahmedgamal54011@gmail.com01065476011

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026